Peter Blume-Jensen - 14 Feb 2025 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact for Peter Blume-Jensen
Issuer symbol
ACRV
Transactions as of
14 Feb 2025
Net transactions value
-$204,502
Form type
4
Filing time
19 Feb 2025, 16:52:40 UTC
Previous filing
25 Nov 2024
Next filing
25 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Tax liability $201,364 -37,152 -1.6% $5.42 2,305,685 14 Feb 2025 Direct F1, F2
transaction ACRV Common Stock Tax liability $3,138 -579 -0.18% $5.42 316,177 14 Feb 2025 See Footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
F2 These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
F3 These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.